Skip to main content
. 2021 May 26;11(5):103. doi: 10.1038/s41408-021-00494-4

Table 2.

Recommended management strategies for corneal events observed in patients receiving belamaf.

Strategy Proposed purpose Directions
Dose modifications (delays and reductions) To limit the corneal exposure of belamaf, as the corneal surface regenerates and repairs itself11 • The eye care professional will determine the highest grade/severity of the corneal event per KVA scale (Table 1), clearly communicate this to the hematologist/oncologist, and continue to monitor these events22,23. The hematologist/oncologist will delay and/or reduce belamaf dose based on the KVA scale guidelines for the most severe eye examination finding
Regular use of preservative-free lubricant eye drops To lubricate the cornea and relieve discomfort of subjective dry eye symptoms29; may decrease risk of corneal symptoms23 • Advise patients to use preservative-free lubricant eye drops at least 4 times a day in both eyes, starting with the first infusion and continuing until end of treatment22,23
Avoiding use of contact lenses unless clinically warranted. An eye care professional may direct the patient to use bandage contact lenses Contact lenses may irritate the cornea30. Bandage contact lenses help protect and aide in repair of the corneal epithelium27

• Begin at the first infusion and continue throughout treatment22,23

• Relevant to both eyes

Belamaf belantamab mafodotin, KVA keratopathy and visual acuity.